Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on December 8th, 2023%
The developer of an experimental immunotherapy delivering nanoscale payloads to treat pancreatic cancer says the treatment received fast-track status from the Food and Drug Administration. . . . → Read More: Nanotech Pancreatic Cancer Immunotherapy Gains FDA Fast Track
By Alan, on December 4th, 2023%
A company developing DNA into a feasible method for large-scale data storage unveiled a credit card-sized device using DNA for off-line data storage. . . . → Read More: DNA Data Company Creates Portable Storage Media
By Alan, on December 1st, 2023%
A collaboration between biotechnology and dairy products businesses seeks to identify peptides in milk to form into dietary supplements for people with mood disorders. . . . → Read More: Partnership to Discover Mental Health Peptides in Milk
By Alan, on November 28th, 2023%
A developer of messenger RNA therapies for respiratory and rare diseases says it received clearance to begin a clinical trial in the U.K. for an inhaled treatment for viral lung conditions. . . . → Read More: Trial Set to Test Inhaled mRNA for Viral Infections
By Alan, on November 21st, 2023%
A challenge competition with a $50 million purse seeks new strategies to attack the global substance abuse epidemic, including personalized diagnostics and treatments. . . . → Read More: Challenge Seeks Precise Addiction Strategies, Biomarkers, Treatments
By Alan, on November 17th, 2023%
Health authorities in Sweden authorized the start of a clinical trial testing insulin-producing cells from donors engineered to prevent immune reactions in people with type 1 diabetes. . . . → Read More: Trial Okayed to Transplant Donated Islet Cells for Type 1 Diabetes
By Alan, on November 16th, 2023%
Generate:Biomedicines describes its Chroma generative A.I. model in yesterday’s issue of the journal Nature, and is making the model available as open source through GitHub. . . . → Read More: Generative A.I. Designs Novel Synthetic Proteins
By Alan, on November 15th, 2023%
A clinical trial in a small group of participants suggests a cannabinoid drug is safe and well-tolerated, and reduces agitation among patients with Alzheimer’s disease. . . . → Read More: Cannabinoid Shown Safe, Lowers Agitation in Alzheimer’s Patients
By Alan, on November 14th, 2023%
A company formed earlier this year is developing precision treatments for bacteria resistant to conventional antibiotics, and raising £4.3 million ($US 5.4 million) in seed funds. . . . → Read More: Start-Up Developing Precision Antibiotics for Resistant Bacteria
By Alan, on November 10th, 2023%
Results of a clinical trial show a peanut allergy treatment formulated as a toothpaste can safely deliver immunotherapy to raise recipients’ peanut tolerance. . . . → Read More: Peanut Allergy Toothpaste Shown Safe in Trial
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|